Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.44 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16758798 | 0.90 | SCN9A (0.40) | SCN9ASCN5A | |
| SCHEMBL16448711 | 0.87 | SCN9A (0.63) | SCN9A | |
| SCHEMBL15535576 | 0.86 | SCN9A (0.64) | SCN9A | |
| SCHEMBL30261290 | 0.85 | SCN9A (0.45) | SCN9ASCN5APARP10PARP15 | |
| SCHEMBL15558549 | 0.85 | SCN9A (0.64) | SCN9ASCN5A | |
| SCHEMBL30261680 | 0.84 | SCN9A (0.52) | SCN9ASCN5APARP10PARP15 | |
| SCHEMBL16759564 | 0.82 | SCN7A (0.56) | SCN9ASCN5A | |
| SCHEMBL16771006 | 0.80 | SCN9A (0.57) | SCN9ASCN5A | |
| SCHEMBL17061824 | 0.80 | SCN9A (0.57) | SCN9ASCN5A | |
| SCHEMBL15557780 | 0.78 | SCN9A (0.53) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2023028077-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | SCN9A 38/4885SCN5A 4/4885PARP10 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.